Drug Profile
MT 5625
Alternative Names: MT-5625Latest Information Update: 17 Feb 2023
Price :
$50
*
At a glance
- Originator Medicago
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Rotavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rotavirus infections
Most Recent Events
- 17 Feb 2023 Discontinued - Phase-I for Rotavirus infections (In adolescents, In children, In infants, Prevention, In volunteers) in South Africa (IM) (Mitsubishi Tanabe Pharma Corporation pipeline, February 2023)
- 17 Feb 2023 Discontinued - Phase-I for Rotavirus infections (In children, In infants, Prevention, In volunteers, In adults) in Australia (IM) (Mitsubishi Tanabe Pharma Corporation pipeline, February 2023)
- 22 Oct 2021 Phase-I development is still ongoing in Rotavirus-infections (In adolescents, In children, In infants, Prevention, In volunteers) in South Africa (IM,Injection) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)